Back to Journals » ImmunoTargets and Therapy » Volume 3

ImmunoTargets and Therapy


Archive: Volume 3, 2014

Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Nguyen T, Urban J, Kalinski P

ImmunoTargets and Therapy 2014, 3:135-150

Published Date: 6 October 2014

Nanocarrier-based immunotherapy in cancer management and research

Singh MS, Bhaskar S

ImmunoTargets and Therapy 2014, 3:121-134

Published Date: 26 June 2014

Hairy cell leukemia – immunotargets and therapies

Basheer F, Bloxham DM, Scott MA, Follows GA

ImmunoTargets and Therapy 2014, 3:107-120

Published Date: 24 June 2014

Clinical potential of apremilast in the treatment of psoriatic arthritis

Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A

ImmunoTargets and Therapy 2014, 3:91-96

Published Date: 9 June 2014

Emerging options for the treatment of melanoma – focus on ipilimumab

Roddie C, Peggs KS

ImmunoTargets and Therapy 2014, 3:67-78

Published Date: 17 March 2014

Interleukin-17 and type 17 helper T cells in cancer management and research

Llosa NJ, Geis AL, Thiele Orberg E, Housseau F

ImmunoTargets and Therapy 2014, 3:39-54

Published Date: 10 March 2014

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

Arnason JE, Brown JR

ImmunoTargets and Therapy 2014, 3:29-38

Published Date: 24 January 2014

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R

ImmunoTargets and Therapy 2014, 3:19-28

Published Date: 27 December 2013

Implications of chemokine receptors and inflammatory lipids in cancer

Rolin J, Maghazachi AA

ImmunoTargets and Therapy 2014, 3:9-18

Published Date: 24 December 2013